arrow
B

Burgess B. Freeman

st jude childrens research hospital
H指数:25
被引数:2,470

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors

靶向p53通路治疗非典型性横纹肌样瘤

2026-01-010
PRE
Nuclear Transport as a Therapeutic Vulnerability in ZFTA-RELA Ependymoma

ZFTA-RELA室管膜瘤中核转运作为治疗性易损靶点

2025-11-010
OAAI
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity

RBM39降解剂通过激活固有免疫来清除神经母细胞瘤,尽管存在癌细胞可塑性。

2025-09-170
OAAI
Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage ambiguous leukemia

维奈克拉联合吉特利替尼在FLT3突变BCL11B-a谱系模糊性白血病的体外模型中是有效的。

Blood
IF23.1
2025-08-180
OA
Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk

儿童 γ δ t-all的生物学和临床分析将LMO2/STAG2重排确定为极高风险

2024-06-242
PRE
Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy

卡马替尼是MET融合驱动的小儿高级别胶质瘤的有效治疗方法,并与放疗协同作用

2024-06-072
OAAI
Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300/CBP inhibition
2024-04-251
OAAI
Selective modulation of the androgen receptor AF2 domain rescues degeneration in spinal bulbar muscular atrophy (vol 24, pg 427, 2018)
2024-01-080
OA
ATM inhibition enhances the efficacy of radiation across distinct molecular subgroups of pediatric high-grade glioma

ATM抑制增强了小儿高级别神经胶质瘤不同分子亚群的辐射功效

2023-03-275
OA
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
2021-11-0944
OAAI
Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma
2021-07-0238
OAAI
Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine
2021-05-3110
OAAI
Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial
2020-08-0145
OAAI